The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Donald S. Silverberg(Tel Aviv Sourasky Medical Center), Adrian Iaina(Tel Aviv Sourasky Medical Center), Doron Schwartz, Zodi Agbaria, Miriam Blum, Shoshana Steinbruch, M Irony, T Yachnin, V Deutsch, R Baruch
PubMed
March 1, 2001
Cited by 76
Related Papers
Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial
|The Lancet|2000|1k
The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations
|Journal of the American College of Cardiology|2000|729
The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study
|Journal of the American College of Cardiology|2001|645
Randomised crossover trial of naltrexone in uraemic pruritus
|The Lancet|1996|298